Form 8-K - Current report:
SEC Accession No. 0001438533-25-000034
Filing Date
2025-05-16
Accepted
2025-05-16 16:13:55
Documents
14
Period of Report
2025-05-15
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tvtx-20250515.htm   iXBRL 8-K 60544
2 EX-99.1 ex991_8-kx20250515eip.htm EX-99.1 213173
  Complete submission text file 0001438533-25-000034.txt   440793

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tvtx-20250515.xsd EX-101.SCH 1782
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tvtx-20250515_lab.xml EX-101.LAB 22804
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tvtx-20250515_pre.xml EX-101.PRE 13046
16 EXTRACTED XBRL INSTANCE DOCUMENT tvtx-20250515_htm.xml XML 2830
Mailing Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130
Business Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130 888-969-7879
Travere Therapeutics, Inc. (Filer) CIK: 0001438533 (see all company filings)

EIN.: 262383102 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36257 | Film No.: 25959397
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)